India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
Nomophobia: Mental distraction given by the digital world Mobile phones have become as indispensable as eating, sitting, and wearing. Rather, they are necessary even if they do not have friends. However, the current generation cannot live without mobile phones. Mobile phones have now become an integral part of life. These devices that facilitate communication, entertainment, and access to information have had a profound impact on our daily lives. However, this ease has brought a new challenge - nomophobia. The Nepali film 'Jhilko', which was released a few days ago, has raised serious questions in society by raising the issue of nomophobia in the context of child mental health. A scene from the film Jhilko, which raises the topic of nomophobia. Director Yadav Kumar Bhattarai has presented nomophobia in the context of children through Jhilko and has presented the impact of excessive use of digital media on children's mental health in an artistic and sensitive manner. What i...